Low-dose pembrolizumab for relapsed/refractory Hodgkin lymphoma: high efficacy with minimal toxicity
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Hematology"
DOI: 10.1007/s00277-017-2931-z
Abstract: Five patients with refractory/relapsed classical Hodgkin lymphoma (cHL), four having failed multiple lines of chemotherapy and brentuximab vedotin, were treated with low-dose pembrolizumab (median dose 100 mg, range: 100–200 mg, every 3 weeks). Complete response (CR) was achieved… read more here.
Keywords: minimal toxicity; low dose; hodgkin lymphoma; pembrolizumab ... See more keywords